1y return+204.4%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since March 31, 2024: $202 against $143 in the S&P 500.2
TCG Crossover Management, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| ABVXAbivax Sa American Depositary Shares | $800.6M | 19.2% | −7.3% |
| TNGXTango Therapeutics Inc | $283.9M | 6.8% | −13.8% |
| CGONCg Oncology Inc | $260.8M | 6.3% | |
| COGTCogent Biosciences Inc | $187.9M | 4.5% | −1.9% |
| IMVTImmunovant Inc | $171.8M | 4.1% | |
| SYRESpyre Therapeutics Inc | $168.7M | 4.1% | |
| DNTHDianthus Therapeutics Inc | $163.4M | 3.9% | |
| MIRMMirum Pharmaceuticals Inc | $124.3M | 3.0% | |
| ZLABZai Lab Ltd-adr | $116.6M | 2.8% | New |
| AMLXAmylyx Pharmaceuticals Inc | $112.1M | 2.7% | |
| GLUEMonte Rosa Therapeutics Inc | $111.9M | 2.7% | |
| BCRXBiocryst Pharmaceuticals Inc | $110.2M | 2.6% | |
| VORVor Biopharma Inc | $104.4M | 2.5% | |
| TYRATyra Biosciences Inc | $103.8M | 2.5% | |
| DYNDyne Therapeutics Inc | $102.5M | 2.5% | |
| IRONDisc Medicine Inc | $98.1M | 2.4% | |
| RLAYRelay Therapeutics Inc | $80.0M | 1.9% | |
| SVRASavara Inc | $76.2M | 1.8% | |
| AURAAura Biosciences Inc | $67.7M | 1.6% | New |
| RVMDRevolution Medicines Inc | $63.8M | 1.5% | −40.9% |
| TRAXFirst Tracks Biotherapeutics | $58.3M | 1.4% | New |
| KODKodiak Sciences Inc | $56.3M | 1.4% | |
| AVTXAvalo Therapeutics Inc | $55.8M | 1.3% | +308.6% |
| LBRXLb Pharmaceuticals Inc | $47.0M | 1.1% | −21.3% |
| IPSCCentury Therapeutics Inc | $43.4M | 1.0% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc | September 30, 2024 | +454.3% | $112.1M |
| SYRESpyre Therapeutics Inc | September 30, 2025 | +429.7% | $168.7M |
| COGTCogent Biosciences Inc | December 31, 2021 | +351.0% | $187.9M |
| DNTHDianthus Therapeutics Inc | December 31, 2024 | +347.2% | $163.4M |
| RVMDRevolution Medicines Inc | September 30, 2025 | +301.0% | $63.8M |
| RLAYRelay Therapeutics Inc | September 30, 2025 | +258.4% | $80.0M |
| TYRATyra Biosciences Inc | December 31, 2021 | +127.0% | $103.8M |
| MBXMbx Biosciences Inc | September 30, 2024 | +112.5% | $35.9M |
| LBRXLb Pharmaceuticals Inc | September 30, 2025 | +105.5% | $47.0M |
| AVTXAvalo Therapeutics Inc | September 30, 2024 | +94.5% | $55.8M |
Sold off last quarter
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $170.3M
- FULCFulcrum Therapeutics Inc was $40.3M
- LQDALiquidia Technologies Inc was $15.2M
- Urogen Pharma LtdCUSIP M96088105 was $7.3M
- GPCRStructure Therapeutics Inc was $6.8M
- UPBUpstream Bio Inc was $1.6M
- VTGNVistagen Therapeutics Inc was $1.5M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +21.8% | +14.8% |
| March 31, 2026 | +8.6% | −4.6% |
| December 31, 2025 | +42.7% | +2.4% |
| September 30, 2025 | +61.3% | +7.8% |
| June 30, 2025 | +17.3% | +10.5% |
| March 31, 2025 | −26.8% | −4.6% |
| December 31, 2024 | −20.3% | +2.1% |
| September 30, 2024 | +14.3% | +5.4% |
| June 30, 2024 | −15.2% | +4.0% |
| December 31, 2023 | +24.9% | +11.2% |
| September 30, 2023 | −8.2% | −3.6% |
| June 30, 2023 | +27.7% | +8.3% |
| March 31, 2023 | −0.2% | +7.0% |
| December 31, 2022 | +17.9% | +7.1% |
| September 30, 2022 | +34.3% | −5.3% |
| June 30, 2022 | −15.3% | −16.5% |
| March 31, 2022 | −11.0% | −4.9% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: TCG Crossover Management, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1839948&type=13F-HR&dateb=&owner=include&count=40CIK 1839948
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1839948/000121465926010290/Filed August 14, 2026 · accession 0001214659-26-010290